Effect of Residual Retinal Fluid on Visual Function in Ranib
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
-Vision gains were greater in eyes with residual versus resolved subretinal fluid.

-Vision gains were lower in eyes with residual versus resolved intraretinal fluid.

-Fluid-vision relationships are more complex than determining a wet or dry macula.

A Study was conducted to investigate the relationship between retinal fluid and vision in ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD).

917 patients aged more than 50 years with subfoveal nAMD associated with subretinal (SRF) and/or intraretinal fluid (IRF) at baseline, screening, or week 1 were included.

Results:
--Baseline BCVA was higher with residual versus resolved SRF at M12, (58.8 letters) and M24 (59.3 letters)
--Mean BCVA change (adjusted for baseline) to M12 was greater with residual versus resolved SRF, but lower with residual versus resolved IRF.
--Eyes with residual SRF (no IRF) exhibited the largest mean BCVA gains (M12, +14.1 letters; M24, +13.2), followed by resolved SRF/IRF (M12, +10.6 letters; M24, +10.0), residual SRF/IRF (M12, +7.2 letters; M24, +8.5), and residual IRF only (M12, +5.5 letters; M24, +3.6).

Conclusively, vision outcomes through M24 were better in ranibizumab-treated eyes with residual versus resolved SRF, and worse with residual versus resolved IRF. Presence of residual retinal fluid requires a more complex and nuanced assessment and interpretation in the context of nAMD management.

Source: https://www.sciencedirect.com/science/article/abs/pii/S0002939421003585?dgcid=rss_sd_all
Like
Comment
Share